Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3.
|
9635572 |
1998 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus alterations in the beta-catenin gene frequently are selected for during liver tumorigenesis and suggest that disregulation of the Wnt-beta-catenin pathway is a major event in the development of HCC in humans and mice.
|
9671767 |
1998 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutant forms of beta-catenin have been discovered in colon cancers that retain wild-type APC genes, and also in melanomas, medulloblastomas, prostate cancer and gastric and hepatocellular carcinomas.
|
10201372 |
1999 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.
|
10435629 |
1999 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data indicate that activation of the Wnt/beta-catenin pathway in HCC results mainly from somatic mutations in the beta-catenin gene and may promote tumor progression by stimulating tumor cell proliferation.
|
10487827 |
1999 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recently, beta-catenin, one of the key components of the Wnt signaling pathway, has been found to be mutated in about 20% of HCCs, suggesting a role of the Wnt pathway in their development.
|
10595907 |
1999 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that accumulation of beta-catenin resulting from genetic mutations is a frequent event in non-fibrolamellar type hepatocellular carcinoma.
|
10597262 |
1999 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present results indicate that (1) mutation of exon 3 of the beta-catenin gene can lead to beta-catenin accumulation, although other mechanisms of accumulation may also operate in HCC, and (2) beta-catenin accumulation and mutation of the beta-catenin gene are not early events in hepatocarcinogenesis, and may be associated with the malignant progression of HCC.
|
10665646 |
1999 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in CTNNB1 (encoding beta-catenin) or APC (adenomatous polyposis coli) have been reported in human neoplasms including colon cancers and hepatocellular carcinomas (HCCs).
|
10700176 |
2000 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found a point mutation of beta-catenin in one of nine HCCs in human and a deletion of it in Hep G2 cell line.
|
10811985 |
2000 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest mechanisms for beta-catenin mutations differ between HBV-related and non-HBV-related HCCs, and that beta-catenin mutation is a favorable prognostic factor related to low stage. beta-Catenin mutation was associated with nuclear expression of the protein (P: < 0.00001), but we failed to detect point or large fragment deletion mutation in 39 HCCs with nuclear beta-catenin expression, presumably wild-type protein.
|
10980116 |
2000 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results suggest that beta-catenin mutation plays an important role in the tumourigenesis of a subset of HCC of good prognosis, and that mutant and wild-type nuclear beta-catenin proteins are not functionally equivalent.
|
11169521 |
2001 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of the p16INK4a (p16) tumor suppressor gene by promoter hypermethylation and mutation within exon 3 of beta-catenin represent two of the more common gene alterations in human hepatocellular carcinoma (HCC).
|
11238187 |
2001 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations affecting phosphorylation sites in the beta-catenin gene have been implicated in the development of human and rodent hepatocellular carcinomas (HCCs).
|
11280770 |
2001 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations of CTNNB1 were identified in five HCCs.
|
11429783 |
2001 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Review of the data from previous studies in HCC showed that beta-catenin mutations were more frequent in HCV-associated HCC than in HBV-associated ones.
|
11443619 |
2001 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The expression of beta-catenin was found to be heterogeneously distributed not only in various histological grades of the same tumor but also in areas of the same histological grade. p53 and beta-catenin gene mutations were detected in 1 tumor respectively, both of which were second primary HCCs and also recurred later.
|
11477549 |
2001 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Axin, an important regulator of beta-catenin, is frequently mutated in human hepatocellular carcinomas (HCCs), and transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC cells as well as in colon cancer cells.
|
11526492 |
2001 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Using in situ hybridization, the signal corresponding to beta-catenin gene exon 3 mRNA was particularly strong in cytoplasm of HCC when compared with those of paracancerous tissues and normal liver tissues.
|
11570580 |
2001 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Aberrant expression of the Wnt-beta-catenin pathway and enzymes for DNA replication also could contribute to the pathogenesis of HCC.
|
11752456 |
2001 |